Synchron secures $200m to advance Stentrode platform commercialisation
US-based company Synchron has raised $200 million in a Series D funding round to support the commercial rollout of its Stentrode brain-computer interface (BCI) platform and to develop next-generation neurointerfaces.
The investment round was led by Double Point Ventures, with participation from ARCH Ventures, Bezos Expeditions, Khosla Ventures, METIS, and NTI. New investors joining include the Australian National Reconstruction Fund (NRF), Qatar Investment Authority (QIA), T.Rx Capital, K5 Global, IQT, and Protocol Labs.
Synchron plans to use this funding to accelerate clinical trials and expand its multidisciplinary team to further enhance its innovative BCI technology.
“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis,” said Tom Oxley, founder and CEO of Synchron. “This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a major breakthrough – a next-generation, transcatheter high-channel whole-brain interface.”
Investment Purpose and Future Plans
- Expand the Stentrode commercial platform globally.
- Advance clinical research and testing programs.
- Grow the company's operational and research teams.
The company’s initiative marks a major step in integrating advanced brain-computer interfaces into everyday medical applications for people with severe mobility limitations.
Author’s Summary
Synchron’s $200 million funding round positions its non-surgical brain-computer interface closer to global adoption, marking a key milestone in neurotechnology commercialization.